Krystal Biotech, Inc. (KRYS)

NMS – Real Time Price. Currency in USD

310.31

-2.57 (-0.82%)

At close: May 12, 2026, 4:00 PM EDT

11.05.2026

This Profitable Biotech Stealthily Climbs Into A Buy Zone

This genetic disorder treatment developer's stock hit a buy point after the biotech's first-quarter earnings report last week.

10.05.2026

Krystal Biotech: Vyjuvek Is Not The Primary Asset

Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow and 95% gross margins since FDA approval. KRYS is rated Buy, justified by a robust pipeline—especially oncology flagship KB707—and a $1B cash position supporting R&D without dilution risk. VYJUVEK's international rollout and pipeline catalysts could drive annual net income to $1.8–$2.9B, with forward PE potentially as low as 2.9–4.6.

07.05.2026

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.

06.05.2026

Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027

Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%. KRYS's robust balance sheet ($823M cash and negligible debt) and disciplined capital allocation fund a broad clinical pipeline without dilution risk. Two registrational readouts in 2026 and two more enrolling in 2027, position KRYS for significant pipeline-driven upside beyond Vyjuvek.

05.05.2026

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.

05.05.2026

Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus

KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.

04.05.2026

Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

04.05.2026

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) registrational data readouts in 2026 FDA grants platform technology designation for KB407 (CF) and KB111 (HHD) Strong balance sheet, ending the quarter with $1.0 billion in cash and investments PITTSBURGH, May 04, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the first quarter ending March 31, 2026 and provided a business update. “Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S.

17.02.2026

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet, ending the quarter with $955.9 million in cash and investments PITTSBURGH, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. “In 2025, Krystal made meaningful progress on our mission to serve patients with dystrophic epidermolysis bullosa around the world, while continuing to build the global infrastructure required to scale our impact,” said Krish S.

11.01.2026

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced selected preliminary unaudited 2025 financial results, including fourth quarter and full year 2025 VYJUVEK® net product revenue, and outlined the Company's strategic vision to drive the next stage of growth of its rare disease business.

25.07.2025

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family

Krystal Biotech, Inc. (KRYS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Krystal Biotech, Inc. (KRYS)

This Profitable Biotech Stealthily Climbs Into A Buy Zone

Krystal Biotech: Vyjuvek Is Not The Primary Asset

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

This Profitable Biotech Stealthily Climbs Into A Buy Zone

Krystal Biotech: Vyjuvek Is Not The Primary Asset

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Search stocks

Krystal Biotech, Inc. (KRYS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Krystal Biotech, Inc. (KRYS)

This Profitable Biotech Stealthily Climbs Into A Buy Zone

Krystal Biotech: Vyjuvek Is Not The Primary Asset

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

This Profitable Biotech Stealthily Climbs Into A Buy Zone

Krystal Biotech: Vyjuvek Is Not The Primary Asset

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results

Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript

Videos

No Data

Press releases

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa